HE 2200

Drug Profile

HE 2200

Alternative Names: androstenetriol; Reversionex

Latest Information Update: 29 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Virginia Commonwealth University
  • Developer Hollis-Eden Pharmaceuticals
  • Class Antihyperlipidaemics; Hormones
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Hypercholesterolaemia; Immunodeficiency disorders; Inflammatory bowel diseases; Multiple sclerosis; Neutropenia; Shock

Most Recent Events

  • 18 Aug 2003 Hollis-Eden has completed enrolment in a phase II trial for hypercholesterolaemia
  • 22 Apr 2003 Phase-II clinical trials in Immunodeficiency disorders in USA (SC)
  • 11 Mar 2003 HE 2200 is available for licensing (http://www.holliseden.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top